| 【Company Research】Simcere Pharmaceutical (2096 HK) – Innovative drug business continues to grow |
| 【Company Research】Great Wall Motor (2333 HK) – Awaiting new PHEVs |
| 【Company Research】UEG (467 HK) – A mixed bag; volume growth is still the key |
| 【Company Research】China Meidong Auto (1268 HK) – Lingering industry headwinds amid high valuation |
| 【Company Research】Mengniu Dairy (2319 HK) – Subpar growth target but good corporate governance practice could stabilize shareholders’ return |
| 【Company Research】Tongda (698 HK) – FY22 results below; GPM recovery on better product mix |
| 【Company Research】Chinasoft (354 HK) – On a slow road to recovery |
| 【Company Research】Botanee Biotech (300957 CH) – ESOP targets stabilize earnings expectation but sentiment overhang remains |
| 【Company Research】GAC Group (2238 HK) – Impairment as always; eyes on Aion’s upmarket |
| CMBI Fixed Income: Hopson: weaker but much better than peers FY22 results |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
